Ruxolitinib inhibits IFNγ licensing of human bone marrow derived Mesenchymal Stromal Cells

BACKGROUND: Ruxolitinib is a JAK2/JAK1 inhibitor which blocks inflammatory JAK-STAT signaling pathway. Ruxolitinib has been demonstrated to be effective in the treatment of steroid-resistant acute Graft vs Host Disease (GvHD). Ruxolitinib’s effect on inflammatory cells of hematopoietic origin is kno...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Transplant Cell Ther
Päätekijät: Ryan, Molly Mercedes, Patel, Mihir, Hogan, Keenan, Lipat, Ariel Joy, Scandolara, Rafaela, Das, Rahul, Bruker, Charles, Galipeau, Jacques, Chinnadurai, Raghavan
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2021
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8110949/
https://ncbi.nlm.nih.gov/pubmed/33965175
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtct.2021.02.002
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia